Sarcomas, a diverse group of cancers originating in bone or soft tissues such as muscle, fat, blood vessels, and nerves, demand prompt diagnosis and specialized care to maximize treatment success, experts say. Despite making up only about 1 percent of adult cancers in the United States, sarcomas encompass more than 100 distinct subtypes, often eluding early detection due to their rarity and subtle symptoms like painless lumps, swollen limbs, or back pain.

Research underscores the consequences of delayed treatment. A 2026 study in the Journal of Surgical Research linked starting therapy more than four weeks after diagnosis with reduced survival rates for common soft tissue sarcomas. This urgency applies even more strongly to ultra-rare sarcomas, which occur at a rate of one case per million or less, according to data from the Sarcoma Foundation of America.

Among these uncommon conditions are rare tumors such as desmoid tumors. Although nonmalignant and lacking the ability to metastasize like typical cancers, desmoids can grow aggressively, causing persistent pain, mobility restrictions, and disfigurement. Physicians and patient advocates emphasize that the noncancerous label should not diminish concern or delay comprehensive care, as these tumors can severely impact quality of life.

“These diseases are often overlooked—overlooked by the public, our communities, and sometimes even health care systems given they are rare,” said Venkat Thiruvallur, senior vice president and head of rare tumors for North America at biopharmaceutical company EMD Serono. Thiruvallur points to frequent diagnostic delays, limited access to specialists, and significant emotional burdens faced by patients with rare tumors.

Experts recommend patients take proactive steps following diagnosis. Connecting with advocacy organizations such as the Sarcoma Foundation of America can provide vital resources and referrals to specialized medical centers. Treatment at these centers, guided by multidisciplinary teams including surgeons, oncologists, radiologists, and pathologists, is critical for accurate subtype identification and tailored therapeutic strategies.

The complexity of sarcoma care often necessitates a combination of surgery, radiation, chemotherapy, and systemic therapies, coordinated to optimize outcomes. Studies by the American Cancer Society indicate that patients treated at experienced sarcoma centers generally achieve better results. For rare tumors like desmoids, global guidelines similarly advocate for management within specialized institutions equipped for multidisciplinary review.

While surgery has historically been a mainstay for treating nonmalignant tumors such as desmoids, repeated procedures can result in functional impairments, including amputations or loss of dexterity. “Repeat surgeries can signal that there are other interventions that need to be considered,” Thiruvallur said, highlighting the need for comprehensive care plans.

Patients are encouraged to engage actively with their treatment teams, focusing not only on tumor response but also on quality-of-life measures such as pain levels and daily function. Thiruvallur emphasized the importance of addressing symptoms patients might otherwise normalize, urging discussions around how treatments affect activities important to individual patients.

Seeking a second opinion, particularly from sarcoma specialists, is advised to confirm diagnoses and explore emerging treatment options, including clinical trials, which may not be widely known outside specialty centers. While some tumors may warrant careful observation, experts caution against complacency, stressing that progression can lead to irreversible damage affecting joints, organs, or nerves.

Thiruvallur’s message to patients is one of support and solidarity: “You are not alone. Advocacy organizations, specialists, and companies working in the field are in it with them.” Companies like EMD Serono continue to focus on developing innovations aimed at reducing pain, restoring mobility, and improving overall quality of life for patients with these rare and challenging diseases.